BRAF represents one of the most frequently mutated protein kinase genes and BRAFV600E mutation may be found in many types of cancer, including hairy cell leukemia (HCL), anaplastic thyroid cancer (ATC), colorectal cancer and melanoma. Herein, a fluorescent probe, based on the structure of the highly specific BRAFV600E inhibitor Vemurafenib (Vem, 1) and featuring the NIR fluorophore cyanine-5 (Cy5), was straightforwardly synthesized and characterized (Vem-L-Cy5, 3), showing promising spectroscopic properties. Biological validation in BRAFV600E-mutated cancer cells evidenced the ability of 3 to penetrate inside the cells, specifically binding to its elective target BRAFV600E with high affinity, and inhibiting MEK phosphorylation and cell growth with a potency comparable to that of native Vem 1. Taken together, these data highlight Vem-L-Cy5 3 as a useful tool to probe BRAFV600E mutation in cancer cells, and suitable to acquire precious insights for future developments of more informed BRAF inhibitors-centered therapeutic strategies.

A cyanine-based NIR fluorescent Vemurafenib analog to probe BRAFV600E in cancer cells

Baldanzi, Caterina;Baglini, Emma;Lepori, Irene;Vitiello, Marianna;Tedeschi, Lorena;Poliseno, Laura;
2023

Abstract

BRAF represents one of the most frequently mutated protein kinase genes and BRAFV600E mutation may be found in many types of cancer, including hairy cell leukemia (HCL), anaplastic thyroid cancer (ATC), colorectal cancer and melanoma. Herein, a fluorescent probe, based on the structure of the highly specific BRAFV600E inhibitor Vemurafenib (Vem, 1) and featuring the NIR fluorophore cyanine-5 (Cy5), was straightforwardly synthesized and characterized (Vem-L-Cy5, 3), showing promising spectroscopic properties. Biological validation in BRAFV600E-mutated cancer cells evidenced the ability of 3 to penetrate inside the cells, specifically binding to its elective target BRAFV600E with high affinity, and inhibiting MEK phosphorylation and cell growth with a potency comparable to that of native Vem 1. Taken together, these data highlight Vem-L-Cy5 3 as a useful tool to probe BRAFV600E mutation in cancer cells, and suitable to acquire precious insights for future developments of more informed BRAF inhibitors-centered therapeutic strategies.
2023
Istituto di Fisiologia Clinica - IFC
Inglese
256
12
Sì, ma tipo non specificato
BRAFV600E
Vemurafenib
Melanoma
Hairy cell leukemia
Fluorescent probe
Cyanine-5
Internazionale
Elettronico
No
13
info:eu-repo/semantics/article
262
Barresi, Elisabetta; Baldanzi, Caterina; Roncetti, Marta; Roggia, Michele; Baglini, Emma; Lepori, Irene; Vitiello, Marianna; Salerno, Silvia; Tedeschi...espandi
01 Contributo su Rivista::01.01 Articolo in rivista
open
   The dark side of BRAFi: hampering pigmentation to boost the efficacy of targeted therapy in melanoma
   AIRC
   735000
File in questo prodotto:
File Dimensione Formato  
prod_482965-doc_198904.pdf

accesso aperto

Descrizione: A cyanine-based NIR fluorescent Vemurafenib analog to probe BRAFV600E in cancer cells
Tipologia: Versione Editoriale (PDF)
Licenza: Creative commons
Dimensione 7.19 MB
Formato Adobe PDF
7.19 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.14243/457994
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 9
  • ???jsp.display-item.citation.isi??? 9
social impact